Research programme: short-chain fatty acid derivatives - HemaQuest
Alternative Names: HQK-1002; HQK-1002SLatest Information Update: 16 Jul 2016
At a glance
- Originator HemaQuest Pharmaceuticals
- Class Fatty acids
- Mechanism of Action Haematopoiesis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Neutropenia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Neutropenia(Chemotherapy-induced) in USA (PO)
- 03 Feb 2010 Preclinical trials in Neutropenia in USA (PO)